{
  "meta": {
    "title": "10_Carcinoma_Breast_-_Staging_Prognosis_Molecular_Types",
    "url": "https://brainandscalpel.vercel.app/10-carcinoma-breast-staging-prognosis-molecular-types-44bbba1a.html",
    "scrapedAt": "2025-11-30T12:35:45.389Z"
  },
  "questions": [
    {
      "text": "Tis classification is used for the staging of:<div class='question-desc-html'><ol>\n<li>Ductal carcinoma in situ (DCIS)</li>\n<li>Lobular carcinoma in situ (LCIS)</li>\n<li>Paget&rsquo;s disease</li>\n<li>Inflammatory carcinoma</li>\n<li>Colloid carcinoma</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1 and 2"
        },
        {
          "id": 2,
          "text": "1, 2 and 4"
        },
        {
          "id": 3,
          "text": "1 and 3"
        },
        {
          "id": 4,
          "text": "3, 4 and 5"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Tis</strong> classification is used for the staging of <strong>ductal carcinoma in situ</strong> and <strong>Paget&rsquo;s disease </strong>only.</p>\n<p>Tis means carcinoma in-situ.&nbsp;</p>\n<ul>\n<li><strong>Tis (DCIS) - </strong>includes ductal carcinoma in situ (DCIS)</li>\n<li><strong>Tis (Paget) - </strong>includes<strong>&nbsp;</strong>Paget's disease of the nipple NOT associated with evident invasive carcinoma and/or carcinoma in situ (DCIS) in the underlying breast parenchyma</li>\n</ul>\n<p>According to the latest American Joint Committee on Cancer (AJCC) classification system (8<sup>th</sup> edition), <strong>lobular carcinoma in situ</strong> (LCIS) is not included in Tis&nbsp;since it is a <strong>benign </strong>entity.</p>\n<p>LCIS is considered a proliferative disease&nbsp;that has a risk of developing breast carcinoma in the future, and hence, it is&nbsp;not included in the classification system.&nbsp;Pleomorphic LCIS is also considered a benign condition.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9905",
      "difficulty": "medium"
    },
    {
      "text": "A postmenopausal lady presented with painless lumps in the right breast. On examination, two lumps of size 6 x 2 cm and 4 x 1 cm were palpated in the upper outer quadrant. Ipsilateral mobile axillary lymph nodes were felt. On evaluation, there was no distant metastasis. What is the TNM staging of this tumor?",
      "choices": [
        {
          "id": 1,
          "text": "T3 N1 M0"
        },
        {
          "id": 2,
          "text": "T1 N1 M0"
        },
        {
          "id": 3,
          "text": "T3 N2 M0"
        },
        {
          "id": 4,
          "text": "T2 N2 M0"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>TNM staging of the tumor is <strong>T3 N1 M0</strong>.</p>\n<p>In the given scenario:</p>\n<ul>\n<li>The bigger lump is 6 cm in size -&nbsp;<strong>T3</strong></li>\n<li>Ipsilateral mobile axillary lymph nodes -&nbsp;<strong>N1</strong>&nbsp;</li>\n<li>No distant metastasis -&nbsp;<strong>M0.&nbsp;</strong></li>\n</ul>\n<p>In tumor size assessment, the <strong>greatest dimension</strong> is taken into consideration. For example, in a 6 x 2 cm lump, 6 cm is taken into account, and the tumor is classified as T3 (&gt;5 cm).&nbsp;If 2 lumps are present in the same breast, staging is according to the&nbsp;<strong>bigger lump.</strong>&nbsp;If lumps are present in <strong>bilateral</strong> breasts,<strong> separate staging</strong>&nbsp;is done for both the lumps.</p>\n<p>Any<strong> contralateral lymph node</strong>&nbsp;involvement is considered as <strong>distant metastasis.</strong></p><hr><h3>Related Pearl: TNM Staging of Carcinoma Breast</h3><table>\n<tbody>\n<tr>\n<td><strong>Tumor (T)</strong></td>\n<td>\n<p><strong>Description</strong></p>\n</td>\n</tr>\n<tr>\n<td>Tx</td>\n<td>\n<p>Primary tumor cannot be assessed</p>\n</td>\n</tr>\n<tr>\n<td>T0</td>\n<td>\n<p>No evidence of primary tumor</p>\n</td>\n</tr>\n<tr>\n<td><strong>Tis (DCIS)</strong></td>\n<td>Ductal carcinoma in situ</td>\n</tr>\n<tr>\n<td><strong>Tis (Paget)</strong></td>\n<td>Paget disease not associated with invasive carcinoma or DCIS</td>\n</tr>\n<tr>\n<td>T1</td>\n<td>\n<p><strong>&le;</strong><strong>2 cm</strong> in greatest dimension</p>\n<p><strong>1mic</strong>&nbsp;&le; 0.1 cm</p>\n<p>1a &gt;0.1 to 0.5 cm</p>\n<p>1b &gt;0.5 to 1 cm</p>\n<p>1c &gt;1 to 2 cm</p>\n</td>\n</tr>\n<tr>\n<td>T2</td>\n<td><strong>&gt;2 but &le;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T3</td>\n<td><strong>&gt;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T4</td>\n<td>\n<p>Tumor of<strong> any size&nbsp;</strong>and -</p>\n<p><strong>4a</strong> &ndash; chest wall involvement (except pectoralis major)<strong>#</strong>&nbsp;</p>\n<p><strong>4b </strong>&ndash; skin involvement in the form of ulceration, peau d&rsquo;orange, satellite nodules &nbsp;</p>\n<p><strong>4c </strong>&ndash; 4a + 4b &nbsp;</p>\n<p><strong>4d</strong> &ndash; Inflammatory breast carcinoma (typical skin changes involving <span>&gt;</span>1/3rd of breast)<strong>*</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Nodes (N)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>N1 mic</td>\n<td>Refers to micrometastasis to Lymph node</td>\n</tr>\n<tr>\n<td>N1</td>\n<td>Ipsilateral <strong>mobile</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2A</td>\n<td>Ipsilateral<strong> fixed or matted</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2B</td>\n<td>Ipsilateral internal mammary <strong>without axillary lymph node</strong> involvement</td>\n</tr>\n<tr>\n<td>N3A</td>\n<td>Ipsilateral infraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td>N3B</td>\n<td>Ipsilateral internal mammary and axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N3C</td>\n<td>Ipsilateral supraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td><strong>Distant metastasis (M)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>M0</td>\n<td>Metastasis absent</td>\n</tr>\n<tr>\n<td>M1</td>\n<td>Metastasis present</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td><strong>T, N</strong></td>\n<td>&nbsp;<strong>M</strong></td>\n</tr>\n<tr>\n<td>Stage 0</td>\n<td>T<sub>is</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IA</td>\n<td>T<sub>1</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IB</td>\n<td>T<sub>0,1</sub>N<sub>1mic</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIA</td>\n<td>T<sub>0,1</sub>N<sub>1</sub> (or) T<sub>2</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIB</td>\n<td>T<sub>2</sub>N<sub>1</sub> (or) T<sub>3</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIA</td>\n<td>T<sub>0,1,2,3</sub>N<sub>2 </sub>(or) T<sub>3</sub>N<sub>1</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIB</td>\n<td><strong>T</strong><sub><strong>4</strong>&nbsp;</sub>N<sub>0,1,2</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIC</td>\n<td>\n<p>Any T,<strong> N<sub>3</sub></strong></p>\n</td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IV</td>\n<td>\n<p>Any T, Any N</p>\n</td>\n<td><strong>M<sub>1</sub></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>#&nbsp;</strong>Chest wall includes Serratus anterior, Intercostal muscles, Ribs.&nbsp;Pectoralis muscle is <strong>not</strong> a part of the chest wall.</p>\n<p><strong>*&nbsp;</strong>Inflammatory breast carcinoma (stage 4d) is characterized by the skin changes of&nbsp;<strong>brawny induration, erythema</strong> with a raised edge, and edema (<strong>peaud&rsquo;orange</strong>) involving <span>&gt;</span>1/3rd of the breast.</p>\n<p>Note: LCIS (lobular carcinoma in situ) is considered a benign condition and not included under Tis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2202ec4c95df457eb86eaf658395ea5dx1280x943.JPEG\" alt=\"Pearl Image\"><p>Prefixes for TNM staging:</p>\n<ul>\n<li><strong>c:</strong>&nbsp;clinical staging (e.g. cT1b)</li>\n<li><strong>p:</strong>&nbsp;pathological (histological) staging</li>\n<li><strong>y:</strong>&nbsp;stage following systemic or radiation therapy (either prior to surgery or as a primary treatment)</li>\n<li><strong>r:</strong>&nbsp;staging at the time of retreatment or recurrence for disease progression</li>\n</ul>\n<p>Suffix for TNM staging:</p>\n<ul>\n<li><strong>m:</strong>&nbsp;multiple primary tumours of the same histology in the same organ, e.g. T2(m) or T2(5), the latter meaning that there are five primary tumours</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0986",
      "difficulty": "easy"
    },
    {
      "text": "A woman came with a 4 x 3 cm lump over the right breast. On examination, the breast appears as shown below. Ipsilateral supraclavicular lymph nodes are palpable with fixed axillary nodes on the left side. What is the most appropriate tumor staging?",
      "choices": [
        {
          "id": 1,
          "text": "T2 N2a M0"
        },
        {
          "id": 2,
          "text": "T4a N3c M0"
        },
        {
          "id": 3,
          "text": "T2 N3c M1"
        },
        {
          "id": 4,
          "text": "T4d N3c M1"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>TNM staging in the given scenario is <strong>T4d N3c M1. </strong></p>\n<ul>\n<li>Tumour of <strong>any size</strong> with typical skin changes involving &gt; 1/3 of breast- <strong>T4d </strong>(Inflammatory breast carcinoma)</li>\n<li>Ipsilateral <strong>supraclavicular</strong> lymph node involvement - <strong>N3c </strong></li>\n<li>Involvement of any <strong>contralateral lymph nodes</strong> indicates distant metastasis - <strong>M1</strong></li>\n</ul><hr><h3>Related Pearl: TNM Staging of Carcinoma Breast</h3><table>\n<tbody>\n<tr>\n<td><strong>Tumor (T)</strong></td>\n<td>\n<p><strong>Description</strong></p>\n</td>\n</tr>\n<tr>\n<td>Tx</td>\n<td>\n<p>Primary tumor cannot be assessed</p>\n</td>\n</tr>\n<tr>\n<td>T0</td>\n<td>\n<p>No evidence of primary tumor</p>\n</td>\n</tr>\n<tr>\n<td><strong>Tis (DCIS)</strong></td>\n<td>Ductal carcinoma in situ</td>\n</tr>\n<tr>\n<td><strong>Tis (Paget)</strong></td>\n<td>Paget disease not associated with invasive carcinoma or DCIS</td>\n</tr>\n<tr>\n<td>T1</td>\n<td>\n<p><strong>&le;</strong><strong>2 cm</strong> in greatest dimension</p>\n<p><strong>1mic</strong>&nbsp;&le; 0.1 cm</p>\n<p>1a &gt;0.1 to 0.5 cm</p>\n<p>1b &gt;0.5 to 1 cm</p>\n<p>1c &gt;1 to 2 cm</p>\n</td>\n</tr>\n<tr>\n<td>T2</td>\n<td><strong>&gt;2 but &le;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T3</td>\n<td><strong>&gt;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T4</td>\n<td>\n<p>Tumor of<strong> any size&nbsp;</strong>and -</p>\n<p><strong>4a</strong> &ndash; chest wall involvement (except pectoralis major)<strong>#</strong>&nbsp;</p>\n<p><strong>4b </strong>&ndash; skin involvement in the form of ulceration, peau d&rsquo;orange, satellite nodules &nbsp;</p>\n<p><strong>4c </strong>&ndash; 4a + 4b &nbsp;</p>\n<p><strong>4d</strong> &ndash; Inflammatory breast carcinoma (typical skin changes involving <span>&gt;</span>1/3rd of breast)<strong>*</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Nodes (N)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>N1 mic</td>\n<td>Refers to micrometastasis to Lymph node</td>\n</tr>\n<tr>\n<td>N1</td>\n<td>Ipsilateral <strong>mobile</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2A</td>\n<td>Ipsilateral<strong> fixed or matted</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2B</td>\n<td>Ipsilateral internal mammary <strong>without axillary lymph node</strong> involvement</td>\n</tr>\n<tr>\n<td>N3A</td>\n<td>Ipsilateral infraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td>N3B</td>\n<td>Ipsilateral internal mammary and axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N3C</td>\n<td>Ipsilateral supraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td><strong>Distant metastasis (M)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>M0</td>\n<td>Metastasis absent</td>\n</tr>\n<tr>\n<td>M1</td>\n<td>Metastasis present</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td><strong>T, N</strong></td>\n<td>&nbsp;<strong>M</strong></td>\n</tr>\n<tr>\n<td>Stage 0</td>\n<td>T<sub>is</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IA</td>\n<td>T<sub>1</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IB</td>\n<td>T<sub>0,1</sub>N<sub>1mic</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIA</td>\n<td>T<sub>0,1</sub>N<sub>1</sub> (or) T<sub>2</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIB</td>\n<td>T<sub>2</sub>N<sub>1</sub> (or) T<sub>3</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIA</td>\n<td>T<sub>0,1,2,3</sub>N<sub>2 </sub>(or) T<sub>3</sub>N<sub>1</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIB</td>\n<td><strong>T</strong><sub><strong>4</strong>&nbsp;</sub>N<sub>0,1,2</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIC</td>\n<td>\n<p>Any T,<strong> N<sub>3</sub></strong></p>\n</td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IV</td>\n<td>\n<p>Any T, Any N</p>\n</td>\n<td><strong>M<sub>1</sub></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>#&nbsp;</strong>Chest wall includes Serratus anterior, Intercostal muscles, Ribs.&nbsp;Pectoralis muscle is <strong>not</strong> a part of the chest wall.</p>\n<p><strong>*&nbsp;</strong>Inflammatory breast carcinoma (stage 4d) is characterized by the skin changes of&nbsp;<strong>brawny induration, erythema</strong> with a raised edge, and edema (<strong>peaud&rsquo;orange</strong>) involving <span>&gt;</span>1/3rd of the breast.</p>\n<p>Note: LCIS (lobular carcinoma in situ) is considered a benign condition and not included under Tis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2202ec4c95df457eb86eaf658395ea5dx1280x943.JPEG\" alt=\"Pearl Image\"><p>Prefixes for TNM staging:</p>\n<ul>\n<li><strong>c:</strong>&nbsp;clinical staging (e.g. cT1b)</li>\n<li><strong>p:</strong>&nbsp;pathological (histological) staging</li>\n<li><strong>y:</strong>&nbsp;stage following systemic or radiation therapy (either prior to surgery or as a primary treatment)</li>\n<li><strong>r:</strong>&nbsp;staging at the time of retreatment or recurrence for disease progression</li>\n</ul>\n<p>Suffix for TNM staging:</p>\n<ul>\n<li><strong>m:</strong>&nbsp;multiple primary tumours of the same histology in the same organ, e.g. T2(m) or T2(5), the latter meaning that there are five primary tumours</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b4d15c8c9dcb457895df99395f3fff8d.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0988",
      "difficulty": "medium"
    },
    {
      "text": "A middle-aged woman presented to the clinic with a 7 x 3 cm lump in the upper outer quadrant of the right breast. On palpation, the lump was found to be fixed to the pectoralis major muscle. What is the T staging of the tumor in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "T4b"
        },
        {
          "id": 2,
          "text": "T3"
        },
        {
          "id": 3,
          "text": "T4a"
        },
        {
          "id": 4,
          "text": "T4c"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In the given scenario, as the lump is 7 cm in size, the T stage of the tumor is<strong> T3</strong> ( <strong>&gt;5 cm</strong>).</p>\n<p>Irrelevant to the size of the tumor, if the tumor shows extension to the <strong>chest wall or skin</strong>, it is classified as <strong>T4</strong>.</p>\n<p>However, there are two <strong>exceptions:</strong></p>\n<ul>\n<li>Invasion or adherence to <strong>pectoralis muscle</strong> in the absence of chest wall involvement does not qualify as T4</li>\n<li>Involvement of the <strong>dermis</strong> alone does not qualify as T4</li>\n</ul><hr><h3>Related Pearl: TNM Staging of Carcinoma Breast</h3><table>\n<tbody>\n<tr>\n<td><strong>Tumor (T)</strong></td>\n<td>\n<p><strong>Description</strong></p>\n</td>\n</tr>\n<tr>\n<td>Tx</td>\n<td>\n<p>Primary tumor cannot be assessed</p>\n</td>\n</tr>\n<tr>\n<td>T0</td>\n<td>\n<p>No evidence of primary tumor</p>\n</td>\n</tr>\n<tr>\n<td><strong>Tis (DCIS)</strong></td>\n<td>Ductal carcinoma in situ</td>\n</tr>\n<tr>\n<td><strong>Tis (Paget)</strong></td>\n<td>Paget disease not associated with invasive carcinoma or DCIS</td>\n</tr>\n<tr>\n<td>T1</td>\n<td>\n<p><strong>&le;</strong><strong>2 cm</strong> in greatest dimension</p>\n<p><strong>1mic</strong>&nbsp;&le; 0.1 cm</p>\n<p>1a &gt;0.1 to 0.5 cm</p>\n<p>1b &gt;0.5 to 1 cm</p>\n<p>1c &gt;1 to 2 cm</p>\n</td>\n</tr>\n<tr>\n<td>T2</td>\n<td><strong>&gt;2 but &le;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T3</td>\n<td><strong>&gt;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T4</td>\n<td>\n<p>Tumor of<strong> any size&nbsp;</strong>and -</p>\n<p><strong>4a</strong> &ndash; chest wall involvement (except pectoralis major)<strong>#</strong>&nbsp;</p>\n<p><strong>4b </strong>&ndash; skin involvement in the form of ulceration, peau d&rsquo;orange, satellite nodules &nbsp;</p>\n<p><strong>4c </strong>&ndash; 4a + 4b &nbsp;</p>\n<p><strong>4d</strong> &ndash; Inflammatory breast carcinoma (typical skin changes involving <span>&gt;</span>1/3rd of breast)<strong>*</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Nodes (N)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>N1 mic</td>\n<td>Refers to micrometastasis to Lymph node</td>\n</tr>\n<tr>\n<td>N1</td>\n<td>Ipsilateral <strong>mobile</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2A</td>\n<td>Ipsilateral<strong> fixed or matted</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2B</td>\n<td>Ipsilateral internal mammary <strong>without axillary lymph node</strong> involvement</td>\n</tr>\n<tr>\n<td>N3A</td>\n<td>Ipsilateral infraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td>N3B</td>\n<td>Ipsilateral internal mammary and axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N3C</td>\n<td>Ipsilateral supraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td><strong>Distant metastasis (M)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>M0</td>\n<td>Metastasis absent</td>\n</tr>\n<tr>\n<td>M1</td>\n<td>Metastasis present</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td><strong>T, N</strong></td>\n<td>&nbsp;<strong>M</strong></td>\n</tr>\n<tr>\n<td>Stage 0</td>\n<td>T<sub>is</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IA</td>\n<td>T<sub>1</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IB</td>\n<td>T<sub>0,1</sub>N<sub>1mic</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIA</td>\n<td>T<sub>0,1</sub>N<sub>1</sub> (or) T<sub>2</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIB</td>\n<td>T<sub>2</sub>N<sub>1</sub> (or) T<sub>3</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIA</td>\n<td>T<sub>0,1,2,3</sub>N<sub>2 </sub>(or) T<sub>3</sub>N<sub>1</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIB</td>\n<td><strong>T</strong><sub><strong>4</strong>&nbsp;</sub>N<sub>0,1,2</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIC</td>\n<td>\n<p>Any T,<strong> N<sub>3</sub></strong></p>\n</td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IV</td>\n<td>\n<p>Any T, Any N</p>\n</td>\n<td><strong>M<sub>1</sub></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>#&nbsp;</strong>Chest wall includes Serratus anterior, Intercostal muscles, Ribs.&nbsp;Pectoralis muscle is <strong>not</strong> a part of the chest wall.</p>\n<p><strong>*&nbsp;</strong>Inflammatory breast carcinoma (stage 4d) is characterized by the skin changes of&nbsp;<strong>brawny induration, erythema</strong> with a raised edge, and edema (<strong>peaud&rsquo;orange</strong>) involving <span>&gt;</span>1/3rd of the breast.</p>\n<p>Note: LCIS (lobular carcinoma in situ) is considered a benign condition and not included under Tis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2202ec4c95df457eb86eaf658395ea5dx1280x943.JPEG\" alt=\"Pearl Image\"><p>Prefixes for TNM staging:</p>\n<ul>\n<li><strong>c:</strong>&nbsp;clinical staging (e.g. cT1b)</li>\n<li><strong>p:</strong>&nbsp;pathological (histological) staging</li>\n<li><strong>y:</strong>&nbsp;stage following systemic or radiation therapy (either prior to surgery or as a primary treatment)</li>\n<li><strong>r:</strong>&nbsp;staging at the time of retreatment or recurrence for disease progression</li>\n</ul>\n<p>Suffix for TNM staging:</p>\n<ul>\n<li><strong>m:</strong>&nbsp;multiple primary tumours of the same histology in the same organ, e.g. T2(m) or T2(5), the latter meaning that there are five primary tumours</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0987",
      "difficulty": "medium"
    },
    {
      "text": "During immunohistochemistry for ER, PR status, staining of what percentage of cells indicates positivity?",
      "choices": [
        {
          "id": 1,
          "text": "10%"
        },
        {
          "id": 2,
          "text": "5%"
        },
        {
          "id": 3,
          "text": "1%"
        },
        {
          "id": 4,
          "text": "50%"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The staining of <strong>&ge;1% of cells</strong>&nbsp;is considered <strong>positive.</strong> Expression of estrogen receptor (ER) and progesterone receptor (PR) in breast cancer cells is mainly assessed by immunohistochemistry.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/187a226d0f3f4975af72ac501241ff12x720x341.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0127",
      "difficulty": "hard"
    },
    {
      "text": "A trucut biopsy is obtained from a woman who presented with a breast lump. The biopsy confirms the presence of mucinous carcinoma. Immunohistochemistry shows ER, PR and HER2/neu positive.  What is the molecular subtype of breast cancer in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Luminal A type"
        },
        {
          "id": 2,
          "text": "Basal type"
        },
        {
          "id": 3,
          "text": "Luminal B type"
        },
        {
          "id": 4,
          "text": "Her 2 type"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Breast cancer with ER, PR <strong>+ve</strong> and HER2/neu <strong>+ve</strong> status will be classified as <strong>luminal B type</strong>. It is also known as <strong>triple-positive cancer</strong>. </p>\n<p>Along with ER, PR, and HER2/neu, a <strong>proliferation index</strong> known as the <strong>Ki67 </strong>index is also used.</p>\n<p>Molecular classification of cancers :</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type</strong></td>\n<td><strong>Properties</strong></td>\n</tr>\n<tr>\n<td>Normal-like</td>\n<td>\n<p> Normal histology</p>\n<p> ER, PR <strong>+ve ,</strong>HER2/neu <strong>-ve</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Luminal A (<strong>most common</strong>/</p>\n<p>best prognosis)</p>\n</td>\n<td>\n<p> </p>\n<p> ER, PR <strong>+ve, </strong>HER2/neu <strong>-ve </strong>(Low Ki)</p>\n</td>\n</tr>\n<tr>\n<td>Luminal B</td>\n<td>\n<p>ER, PR <strong>+ve</strong>, HER2/neu <strong>-ve</strong>, Ki-67- <strong>High<br /></strong></p>\n<p>ER, PR <strong>+ve</strong>, HER2/neu <strong>+ve</strong>, Ki-67 <strong>Any</strong></p>\n</td>\n</tr>\n<tr>\n<td>Basal cell (worst prognosis)</td>\n<td>\n<p> <strong>Triple-negative</strong></p>\n<p> (High Ki), Positive for myoepithelial markers - EGFR, CK  5,6,17</p>\n</td>\n</tr>\n<tr>\n<td>HER2-enriched type</td>\n<td>\n<p> ER &amp; PR <strong>–ve, </strong>HER2/neu <strong>+ve</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1033",
      "difficulty": "medium"
    },
    {
      "text": "In breast cancer patients, FISH for gene amplification will be done based on which of the following IHC staining for Her-2/neu?",
      "choices": [
        {
          "id": 1,
          "text": "1+"
        },
        {
          "id": 2,
          "text": "2+"
        },
        {
          "id": 3,
          "text": "3+"
        },
        {
          "id": 4,
          "text": "Gene Amplification is done irrespective of Her 2 Neu status"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Fluorescence in situ hybridization </strong>(FISH)<strong>&nbsp;</strong>should be performed in <strong>all cases of breast tumors</strong>&nbsp;with an immunohistochemistry (<strong>IHC</strong>)<strong> score of 2+.</strong></p>\n<p>Expression of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu in breast cancer cells is mainly assessed by immunohistochemistry.&nbsp;<strong>HER2/neu IHC interpretation:</strong>&nbsp;</p>\n<ul>\n<li>1+ = Negative</li>\n<li>2+ = Equivocal -&nbsp;<strong>FISH</strong> is done to <strong>differentiate</strong> whether the tumor cells are positive or negative for <strong>HER2/neu</strong> expression</li>\n<li>3+ = Positive HER2/neu- complete circumferential&nbsp;membrane staining in &gt;10% of tumor cells</li>\n</ul>\n<p>The given image shows HER2/neu, ER, and PR positivity.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/982edecb127d4d319fad21d8da943b19x720x341.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1545",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is true about Oncotype Dx, a molecular test used for breast cancer?",
      "choices": [
        {
          "id": 1,
          "text": "Used for hormone receptor–negative cancers"
        },
        {
          "id": 2,
          "text": "Is a 21-gene assay"
        },
        {
          "id": 3,
          "text": "Helpful in predicting the advantage of adding radiotherapy"
        },
        {
          "id": 4,
          "text": "Used for lymph node–positive cancers"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Oncotype Dx assay</strong> is a molecular test based on the assessment of <strong>21</strong> genes.</p>\n<p><strong>Higher</strong>&nbsp;<strong>scores</strong> predict increased<strong> benefits</strong> from <strong>chemotherapy</strong>. On the other hand, <strong>lower scores</strong> in this assay predict lesser benefit from chemotherapy and increased <strong>benefit</strong> from <strong>endocrine therapy.</strong></p>\n<div class=\"page\" title=\"Page 878\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>It is used for patients with lymph <strong>node-negative</strong>, <strong>ER-positive</strong> breast cancer.</p>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Newer molecular tests in breast cancer</h3><p>Newer molecular tests for breast cancer have been developed, which help in predicting the advantage of adding <strong>chemotherapy</strong>.&nbsp;These are:</p>\n<ul>\n<li>Oncotype Dx (21-geneassay)</li>\n<li>Mammaprint (70-gene assay)</li>\n<li>EndoPredict (12-gene assay)</li>\n<li>PAM50 (50-gene assay)</li>\n</ul>\n<p><strong>Oncotype Dx </strong>can only be used in<strong> hormone (ER, PR) receptor-positive&nbsp;cancers, </strong>while <strong>mammaprint </strong>can be used in<strong> both </strong>hormone receptor (ER, PR) positive&nbsp;and hormone receptor-negative&nbsp;cancers.&nbsp;</p>\n<p>These tests are used for T<sub>1,2 </sub>N<sub>0</sub> M<sub>0</sub> breast cancers &ndash; (<strong>node-negative, metastasis-negative</strong>). Using these molecular tests, a <strong>recurrence score</strong> (0 &ndash; 100) is calculated.</p>\n<ul>\n<li>If the score is <strong>low</strong>, then there <strong>is no advantage</strong> of adding chemotherapy</li>\n<li>If the score is <strong>high</strong>, then chemotherapy should be <strong>added</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0120",
      "difficulty": "medium"
    },
    {
      "text": "After performing Oncotype Dx for a breast tumor, a low recurrence score is obtained. Which of the following is true regarding management in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Tumor resection with chemotherapy should be done"
        },
        {
          "id": 2,
          "text": "Brachytherapy with chemotherapy should be done"
        },
        {
          "id": 3,
          "text": "Chemotherapy should be used along with hormonal therapy"
        },
        {
          "id": 4,
          "text": "There is no advantage in adding chemotherapy"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>A <strong>low</strong> recurrence score after Oncotype Dx suggests that there is <strong>no survival</strong> <strong>advantage</strong> of adding <strong>chemotherapy</strong>.</p>\n<p>A high recurrence score, on the other hand, suggests that chemotherapy should be added.</p><hr><h3>Related Pearl: Newer molecular tests in breast cancer</h3><p>Newer molecular tests for breast cancer have been developed, which help in predicting the advantage of adding <strong>chemotherapy</strong>.&nbsp;These are:</p>\n<ul>\n<li>Oncotype Dx (21-geneassay)</li>\n<li>Mammaprint (70-gene assay)</li>\n<li>EndoPredict (12-gene assay)</li>\n<li>PAM50 (50-gene assay)</li>\n</ul>\n<p><strong>Oncotype Dx </strong>can only be used in<strong> hormone (ER, PR) receptor-positive&nbsp;cancers, </strong>while <strong>mammaprint </strong>can be used in<strong> both </strong>hormone receptor (ER, PR) positive&nbsp;and hormone receptor-negative&nbsp;cancers.&nbsp;</p>\n<p>These tests are used for T<sub>1,2 </sub>N<sub>0</sub> M<sub>0</sub> breast cancers &ndash; (<strong>node-negative, metastasis-negative</strong>). Using these molecular tests, a <strong>recurrence score</strong> (0 &ndash; 100) is calculated.</p>\n<ul>\n<li>If the score is <strong>low</strong>, then there <strong>is no advantage</strong> of adding chemotherapy</li>\n<li>If the score is <strong>high</strong>, then chemotherapy should be <strong>added</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0123",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not related to breast carcinoma?",
      "choices": [
        {
          "id": 1,
          "text": "Nottingham prognostic index"
        },
        {
          "id": 2,
          "text": "Gail and Claus models"
        },
        {
          "id": 3,
          "text": "Van Nuys prognostic index"
        },
        {
          "id": 4,
          "text": "MACIS prognostic index"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>MACIS</strong> is not used in breast cancer. It is a prognostic index for <strong>thyroid cancer</strong>. &nbsp;</p>\n<p>The&nbsp;Nottingham prognostic index,&nbsp;Gail and Claus models, and Van Nuys prognostic index<strong>&nbsp;</strong>are all <strong>associated</strong> with breast cancer assessment.</p>\n<p><strong>Van Nuys prognostic index</strong>&nbsp;is used to <strong>identify</strong> patients with duct carcinoma in situ (<strong>DCIS</strong>) who do not need radiation therapy.&nbsp;This grading system is based on the following parameters:</p>\n<ul>\n<li>Patient&rsquo;s age</li>\n<li>DCIS nuclear grade and presence of microcalcification</li>\n<li>Size of the lesion</li>\n<li>Width of the surgical margin</li>\n</ul>\n<p>The<strong> Nottingham prognostic index </strong>segregates the patients into four groups and is used to predict the <strong>5-year survival</strong>. It helps to formulate treatment plans.</p>\n<p>Nottingham Prognostic Index = (0.2 &times; Tumor size in cm) + grade + nodes</p>\n<p>The <strong>Gail and Claus models </strong>are&nbsp;used for <strong>assessing</strong> the&nbsp;<strong>risk </strong>of development of<strong> breast carcinoma. </strong>It<strong>&nbsp;</strong>includes the following parameters:</p>\n<ul>\n<li>Number of first-degree relatives with carcinoma breast</li>\n<li>Age at menarche</li>\n<li>Age at first live birth</li>\n<li>Number of breast biopsies</li>\n</ul>\n<p><strong>Claus model</strong> provides individual estimates of <strong>breast cancer risk</strong> according to the decade of life, based on the presence of first- and second-degree relatives with breast cancer and their age at diagnosis.</p>\n<p>Note:&nbsp;Neither the Gail model nor the Claus model accounts for the risk associated with mutations in the breast cancer susceptibility genes BRCA1 and BRCA2.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1035",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most important prognostic factor in a patient with breast carcinoma?",
      "choices": [
        {
          "id": 1,
          "text": "Size of the tumor"
        },
        {
          "id": 2,
          "text": "Axillary lymph node involvement"
        },
        {
          "id": 3,
          "text": "Involvement of skin over the breast"
        },
        {
          "id": 4,
          "text": "Receptor status"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Axillary</strong> <strong>lymph node status</strong>&nbsp;is the most important determinant in the <strong>staging and prognosis</strong> of women with breast cancer.</p>\n<p>In axillary node-negative breast cancer,&nbsp;ER, PR receptor status&nbsp;becomes the most important prognostic factor.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1031",
      "difficulty": "medium"
    },
    {
      "text": "The Van Nuys grading system for ductal carcinoma in situ does not include:",
      "choices": [
        {
          "id": 1,
          "text": "Age of the patient"
        },
        {
          "id": 2,
          "text": "Size of the tumor"
        },
        {
          "id": 3,
          "text": "Hormone receptor staining"
        },
        {
          "id": 4,
          "text": "Presence of microcalcification"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Staining for estrogen and progesterone receptors is not part of the Van Nuys system used for grading DCIS.&nbsp;</p>\n<p>The components of the <strong>Van Nuys prognostic index</strong> (VNPI) are as follows:</p>\n<ul>\n<li>Size of the tumor</li>\n<li>Extent of resection margin&nbsp;</li>\n<li>Histological variant of DCIS - based on nuclear grade, presence of necrosis, presence of microcalcification</li>\n<li>Age&nbsp;of the patient</li>\n</ul>\n<p>Patients with a<strong> high score</strong> in this grading system benefit from <strong>radiotherapy after excision, </strong>whereas those with <strong>low-grade</strong>&nbsp;and&nbsp;<strong>completely excised</strong> tumors, need <strong>no further treatment</strong>.</p>\n<p>A score ranging from<strong> 1 </strong>(lesions with the <strong>best prognosis</strong>) to <strong>3 </strong>(lesions with the <strong>worst prognosis</strong>) is given for each of the four prognostic predictors. Total scores range from 4 (least likely to recur) to 12 (most likely to recur).</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Silverstein Van Nuys prognostic index for DCIS</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<table>\n<tbody>\n<tr>\n<td><strong>Parameters</strong></td>\n<td><strong>Score 1</strong></td>\n<td><strong>Score 2</strong></td>\n<td><strong>Score 3</strong></td>\n</tr>\n<tr>\n<td><strong>Size(mm)</strong></td>\n<td>&le;15</td>\n<td>16-40</td>\n<td>&ge;41</td>\n</tr>\n<tr>\n<td><strong>Margin(mm)</strong></td>\n<td>&ge;10</td>\n<td>1-9</td>\n<td>&lt;1</td>\n</tr>\n<tr>\n<td><strong>Class</strong></td>\n<td>Grade 1 or 2 without necrosis</td>\n<td>Grade 1 or 2 with necrosis</td>\n<td>Grade 3 with or without necrosis</td>\n</tr>\n<tr>\n<td><strong>Age(years)</strong></td>\n<td>&gt;60</td>\n<td>40-60</td>\n<td>&lt;40</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<table>\n<tbody>\n<tr>\n<td>\n<ul>\n<li>Scores 4-7 with &gt;3mm margin: <strong>Excision alone</strong>&nbsp;</li>\n<li>Score 7 with &lt; 3 mm margin, score 8 with &gt; 3mm margin, score 9 with &gt;5mm margin:&nbsp;<strong>Excision with RT</strong></li>\n<li>Score 9 with &lt; 5mm margin &amp; score 10,11,12: <strong>Mastectomy</strong></li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: The type of <strong>microcalcification</strong> seen on imaging, helps in determining the <strong>nuclear grade</strong> of DCIS.<strong>&nbsp;</strong>While<strong>&nbsp;</strong>the<strong> linear</strong> <strong>branching</strong> type of microcalcification is associated with <strong>high </strong>nuclear grade, <strong>fine granular</strong> type is associated with <strong>low </strong>nuclear grade.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3781",
      "difficulty": "medium"
    },
    {
      "text": "A 42-year-old woman presented with a history of painless breast lump measuring 6.2 X 4.5 cm in the left upper outer quadrant and no axillary nodes. Core cut biopsy showed ductal carcinoma in situ. She underwent tumor resection with adequate margins and postoperative HPE showed DCIS with intermediate-grade necrosis and with 6-mm clearance on margins. What is the next step of treatment?",
      "choices": [
        {
          "id": 1,
          "text": "No additional treatment"
        },
        {
          "id": 2,
          "text": "Adjuvant radiotherapy"
        },
        {
          "id": 3,
          "text": "Adjuvant chemotherapy"
        },
        {
          "id": 4,
          "text": "Adjuvant chemoradiotherapy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>According to Silverstein <strong>Van Nuys prognostic index</strong> for DCIS, the <strong>total score is 9. </strong>Hence, the patient would require <strong>adjuvant radiotherapy</strong>.</p>\n<p>Age: 42 years (score 2), size: 62mm (score 3), clearance margin: 6mm (score 2) with intermediate-grade necrotic features (score 2).</p>\n<p>Silverstein Van Nuys prognostic index for DCIS:</p>\n<table>\n<tbody>\n<tr>\n<td>Parameters&nbsp;</td>\n<td>Score 1&nbsp;</td>\n<td>Score 2&nbsp;</td>\n<td>Score 3</td>\n</tr>\n<tr>\n<td>Age (years)&nbsp;</td>\n<td>&ge;61&nbsp;</td>\n<td>40-60</td>\n<td>&lt;40&nbsp;</td>\n</tr>\n<tr>\n<td>Size (mm)&nbsp;</td>\n<td>&le;15 mm&nbsp;</td>\n<td>16-40 mm</td>\n<td>&gt;40 mm&nbsp;</td>\n</tr>\n<tr>\n<td>Margin (mm)</td>\n<td>&ge;10 mm&nbsp;</td>\n<td>1-9 mm&nbsp;</td>\n<td>&lt;1 mm</td>\n</tr>\n<tr>\n<td>Class (grade and necrosis)</td>\n<td>\n<p>Grades 1 and 2&nbsp;</p>\n<p>no necrosis&nbsp;</p>\n</td>\n<td>\n<p>Grades 1 or 2</p>\n<p>with necrosis&nbsp;</p>\n</td>\n<td>Grade 3 with or without necrosis</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Treatment:</p>\n<ul>\n<li aria-level=\"1\">Scores 4-6 with &gt;3mm margin: <strong>Excision alone&nbsp;</strong></li>\n<li aria-level=\"1\">Score 7 with &lt; 3 mm margin, score 8 with &gt; 3mm margin, score 9 with &gt;5mm margin: <strong>Excision with RT</strong></li>\n<li aria-level=\"1\">Score 9 with &lt; 5mm margin &amp; score 10-12: <strong>Mastectomy</strong></li>\n</ul>\n<p>If the patient is&nbsp;<strong>ER/PR+</strong>, adjuvant&nbsp;<strong>hormonal therapy</strong> with tamoxifen or an aromatase inhibitor is indicated. Current data does not support the use of HER-2-directed therapy in DCIS.&nbsp;</p>\n<p>Indications for adjuvant radiotherapy in breast cancer:&nbsp;</p>\n<ul>\n<li>Locally advanced breast cancers (T3, T4, N1, N2, N3)</li>\n<li>Following breast conservation surgery&nbsp;</li>\n<li>After mastectomy if tumor size &ge;5 cm, skin or chest wall involvement, lymphovascular invasion and axillary node-positive for metastasis.</li>\n</ul>\n<p><strong>Post-treatment surveillance</strong>&nbsp;after treatment for DCIS includes history, physical examination, and routine mammography (if applicable).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1169",
      "difficulty": "medium"
    }
  ]
}